Physician profile
Bonnie Sutton
NPI 1699424606
$6,508.40
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,904 · 2023: $3,190 · 2024: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,565 · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,565.32 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,888.29 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $446.01 | 2022-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $442.43 | 2022-2024 | Trulance, Xifaxan |
| Genzyme Corporation | $429.38 | 2022-2024 | |
| Intra-Sana Laboratories | $428.01 | 2022-2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Celgene Corporation | $382.55 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $351.87 | 2022-2024 | Stelara, Tremfya |
| Ardelyx, INC. | $287.45 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $264.93 | 2022-2024 | Dupixent |
| Gilead Sciences, INC. | $264.14 | 2023-2024 | Epclusa |
| Lucid Diagnostics INC. | $222.44 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $186.42 | 2023 | Stelara |
| Evoke Pharma, INC. | $146.03 | 2022-2023 | Gimoti |
| Vivus LLC | $115.49 | 2022-2023 | Pancreaze |
| Merck Sharp & Dohme LLC | $108.14 | 2022-2023 | Dificid, Zerbaxa, Recarbrio |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $107.78 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $79.84 | 2024 | |
| Redhill Biopharma INC. | $68.19 | 2022-2024 | Talicia, Aemcolo |
| Ironwood Pharmaceuticals, INC | $62.58 | 2022-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $57.97 | 2022-2024 | Ocaliva |
| Celltrion USA INC. | $39.14 | 2024 | Zymfentra |
| Pfizer INC. | $37.24 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.22 | 2023 | Gattex |
| Phathom Pharmaceuticals, INC. | $19.54 | 2024 | Voquezna |
| Axonics, INC. | $16.44 | 2022 | |
| Braintree Laboratories, INC. | $14.71 | 2023 | Sutab, Suflave |
| Lilly USA, LLC | $14.17 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonnie Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.